ImmunologyThe Journal of ImmunologyPeer-reviewed
LAG3+ CD8+ T cell Subset Drives HR+/HER2- Breast Cancer Reduction in Bispecific Antibody Armed Activated T Cell Therapy
Robert Weldon Barnes, Archana B. Thakur, Suna Önengüt-Gümüşcü…·Sepideh Dolatshahi
This study identifies LAG3+ CD8+ T cells as key effectors in bispecific antibody armed T cell therapy for HR+/HER2- breast cancer and shows how checkpoint inhibitors can enhance their anti-tumor function.